Cognitive functions in primary central nervous system lymphoma: Literature review and assessment guidelines

Annals of Oncology

Volumn 18, Issue 7, 2007, Pages 1145-1151

  Correa, D D ^a   Maron, L ^b   Harder, H ^c   Klein, M ^d   Armstrong, C L ^e   Calabrese, P ^f   Bromberg, J E C ^c   Abrey, L E ^a   Batchelor, T T ^g   Schiff, D ^h  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Chemotherapy; Cognitive; Neurotoxicity; Primary CNS lymphoma; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN; METHOTREXATE;

ATTENTION DISTURBANCE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; COGNITIVE DEFECT; DIAGNOSTIC VALUE; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; MEMORY DISORDER; MOTOR DYSFUNCTION; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; TREATMENT OUTCOME; WECHSLER INTELLIGENCE SCALE; WECHSLER MEMORY SCALE;

ANTINEOPLASTIC AGENTS; BRAIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; COGNITION DISORDERS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA; NEUROPSYCHOLOGICAL TESTS; NEUROTOXICITY SYNDROMES; QUALITY OF LIFE; RADIOTHERAPY;

EID: 34547840273     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl464     Document Type: Review

References (50)

1. Peterson K, DeAngelis LM. Primary cerebral lymphoma. In Vecht Ch J (ed): Handbook of Clinical Neurology, Vol 24: Neuro-Oncology, part II. Amsterdam: Elsevier Science 1997; 257-268.
2. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859-863.
3. Poortmans PM, Kluin-Nelemans HC, Haáxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group phase II Trial 20962. J Clin Oncol 2003; 21: 4483-4488.
4. Behin A, Delattre J-Y. Neurologic sequelae of radiotherapy on the nervous system. In Schiff D, Wen PY (eds): Cancer Neurology in Clinical Practice. Totowa, NJ: Humana Press Inc. 2003; 173-191.
5. Correa DD, DeAngelis LM, Shi W et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004; 62: 548-555.
6. Harder H, Holtel H, Bromberg JEC et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004; 62: 544-547.
7. DeAngelis LM, Shapiro WR. Drug/radiation interactions and central nervous system injury. In Gutin PH, Lelbel, SA, Sheline GE (eds): Radiation Injury to the Nervous System. New York NY: Raven Press 1991; 361-382.
8. Corry J, Smith JG, Wirth A et al. Primary central nervous system lymphoma: Age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 1998; 41: 615-620.
9. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: No ifs, ands, buts, or sensitivity. J Clin Oncol 2003; 21: 3557-3558.
10. Weitzner MA, Meyers CA. Cognitive functioning and quality of life in malignant glioma patents: A review of the literature. Psychooncology 1997; 6: 169-177.
11. Blay J-Y, Conroy T, Chevreau C et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16: 864-871.
12. Keime-Guibert F, Napolitano M, Delattre JY. Neurological complications of radiotherapy and chemotherapy. J Neurol 1998; 245: 695-708.
13. Laack NN, Brown PD. Cognitive sequelae of brain radiation in adults. Semin Oncol 2004; 31: 702-713.
14. Regine WF, Schmitt FA, Scott CB et al. Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: Results of radiation therapy oncology group trial BR-0018. Int J Radiat Oncol Biol Phys 2004; 58: 1346-1352.
15. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 2006; 24: 1305-1309.
16. Abrey LE, Batchelor TT, Ferreri AJM et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary GNS lymphoma. J Clin Oncol 2005; 23: 5034-5043.
17. Pels H, Deckert-Schulter M, Glasmacher A et al. Primary central nervous system lymphoma: A clinicopathological study of 28 cases, Hematol Oncol 2000; 18: 21-32.
18. Sandor V, Stark-Vancs V, Pearson D et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998; 16: 3000-3006.
19. Correa DD, Anderson ND, Glass A et al. Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: Preliminary findings. Clin Adv Hematol Oncol 2003; 1: 490.
20. Fliessbach K, Urbach H, Helmstaedter C et al. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 2003; 60: 563-568.
21. Fliessbach K, Helmstaedter C, Urbach H et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: A prospective study. Neurology 2005; 64: 1184-1188.
22. Pels H, Schmidt-Wolf IGH, Glasmacher A et al. Primary central nervous system lymphoma: Results of a pilot study and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21: 4489-4495.
23. Schlegel U, Pels H, Glasmacher A et al. Combined systemic and intraventricular chemotherapy in primary GNS lymphoma: A pilot study. J Neurol Neurosurg Psychiatr 2001; 71: 118-122.
24. Herrlinger U, Kuker W, Uhl M et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: Final report. Ann Neurol 2005; 57: 843-847.
25. Crossen JR, Goldman, DL, Dahlborg SA et al. Neuropsychological assessment outcomes of non-acquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy. Neurosurgery 1992; 30: 23-29.
26. McAllister LD, Doolittle ND, Guastadisegni PE et al. Cognitive outcomes and longterm follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000; 46: 51-61.
27. Neuwelt, EA, Guastadisegni PE, Varallyay P et al. Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. Am J Neuroradiol 2005; 26: 258-265.
28. Roman-Goldstein SM, Mitchell P, Crossen JR et al. MR and cognitive testing of patents undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. Am J Neuroradiol 1995; 16: 543-553.
29. Neuwelt EA, Goldamn DA, Dahlborg SA et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Onool 1991; 9: 1580-1590.
30. Dahlborg SA, Henner WD, Crossen JR et al. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 1996; 2: 166-174.
31. Dahlborg SA, Petrillo A, Crossen JR et al. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sci Am 1998; 4: 110-124.
32. Archibald YM, Lunn D, Ruttan LA et al. Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 1994; 80: 247-253.
33. Crossen JR, Garwood D, Glatstein E et al. Neurobehavioral sequlae of cranial irradiation in adults: A review of radiation-induced encephalopathy. J Clin Oncol 1994; 12: 627-642.
34. Schelbel RS, Meyers CA, Levin VA. Cognitive dysfunction following surgery for intracerebral glioma: Influence of histopathology, lesion location, and treatment. J Neurooncol 1996; 30: 61-69.
35. Rao SM, Leo GJ, Bernardin L et al. Cognitive function in multiple sclerosis I. Frequency, patterns, and prediction. Neurology 1991; 41: 685-691.
36. Armstrong CL, Gyato K, Awadalla A et al. A critical review of the effects of therapeutic irradiation on brain: The roots of controversy. Neuropsychol Rev 2004; 14: 65-86.
37. Meyers CA, Smith JA, Bezjak A et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J Clin Oncol 2004; 22: 157-165.
38. Wechsler D. Wechsler Adult Intelligence Scale - 3rd edition (WAIS-III). San Antonio, TX: Harcourt Brace & Go. 1997.
39. Reitan RM, Wolfson D. The Halstead-Reltan Neuropsychological Test Battery. Tucson, AZ: Neuropsychology Press 1985.
40. Schretlen D, Bobholz JH, Brandt J. Development and psychometric properties of the brief test of attention. Clin Neuropsychol 1996; 10: 80-89.
41. Benedict RHB, Schretlen D, Groninger L et al. Hopkins Verbal Learning Test - Revised: Normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 1998; 12: 43-55.
42. Heaton RK, Grant I, Mattheys CG. Comprehensive Norms for an Expanded Halstead-Reltan Battery: Demographic Corrections, Research Findings, and Clinical Applications. Odessa, FL: Psychological Assessment Resources 1991.
43. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C3O: A quality of life instrument for i1se in international trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
44. Osoba D, Aaronson NK, Muller M et al. The development at psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 1996; 5: 139-150.
45. Barona A, Reynolds CR, Chastin R. A demographically based index of premorbid intelligence for the WAIS-R. J Consult Clin Psychol 1984; 52: 885-887.
46. Armstrong CL, Hunter J, Ledakis G et al. Late cognitive and radiographic changes related to radiotherapy: Initial prospective findings. Neurology 2002; 59: 40-48.
47. Benedict RHB, Zgaljardic DJ. Practice effects during repeated administrations of memory tests with and without alternate forms. J Clin Exp Neuropsychol 1998; 20: 339-352.
48. Jacobson NS, Truax P. Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12-19.
49. Batchelor TT, Carson K, O'Neill A et al. NABTT GNS Consortium: The treatment of primary central nervous system lymphoma (PCNSL) with methotrexate and deferred radiotherapy-NABTT 96-07. J Clin Oncoll 2003; 21: 1044-1049.
50. Deangelis LM, Selferheld W, Schold SC et al. Combination chemotherapy and radiotherapy for primary central nervous lymphoma: Radiation Therapy Oncology Group 93-100. J Clin Oncol 2002; 21: 4643-4648.